Key Highlights
- Intuitive Surgical reported second-quarter revenue of $2.89 billion, a 19% year-over-year increase.
- Global procedures using da Vinci and Ion systems grew approximately 16%, with Ion procedures rising approximately 36%.
- Non-GAAP earnings per share reached $2.80, exceeding prior-year results.
- Shares fell sharply today, extending year-to-date declines despite strong operational performance.
Price decline follows earnings release · Market reaction contrasts with financial results · Next catalyst: Full-year 2026 outlook update
Intuitive Surgical reported a solid second quarter, with revenue increasing 19% to $2.89 billion and earnings per share rising to $2.80 on a non-GAAP basis. The company’s robotic surgery platforms saw broad adoption, with global procedures growing approximately 16%, including a 36% increase in Ion procedures and a 15% rise in da Vinci procedures. Despite these gains, shares fell sharply in response to ongoing concerns about external risks, underperforming broader healthcare sector peers.
Earnings Growth Outpaces Expectations, But Market Focuses on Risks
Intuitive Surgical’s second-quarter results exceeded prior-year performance, with non-GAAP net income reaching $1.00 billion, or $2.80 per share, compared to $0.80 billion in the same period last year. The company expanded its installed base of da Vinci systems by 12% to 11,710 units as of June 30, 2026, while Ion systems grew 21% to 1,096 units. Revenue growth was supported by an 18% increase in instruments and accessories sales, which totaled $1.73 billion, and a rise in systems revenue to $685 million.
The quarter also included a benefit of $28 million from tariff refunds, contributing $0.08 to earnings per share. However, investor attention shifted to potential headwinds, leading to a selloff despite the strong financial performance.
Procedure Growth Highlights Demand, While Tariffs Pose Challenges
The company’s core business demonstrated resilience, with da Vinci procedures increasing approximately 15% and Ion procedures rising approximately 36%, reflecting continued adoption of minimally invasive surgical techniques. Intuitive placed 468 da Vinci systems in the quarter, including 246 of its latest model, compared to 395 placements in the prior-year period. Systems revenue benefited from higher average selling prices and an expanding lease installed base, while instruments and accessories revenue was driven by procedure volume growth.
Management noted that tariffs could reduce non-GAAP gross profit margins by up to 1% in 2026 if current trade policies remain unchanged, adding a layer of uncertainty to the outlook.
Stock Declines as Investors Assess Long-Term Pressures
Intuitive Surgical’s shares, already down significantly year-to-date, fell further following the earnings release. The decline reflects investor concerns about factors beyond the quarterly results, including the potential impact of tariffs, competitive dynamics, and valuation considerations. As a leader in robotic-assisted surgery, Intuitive maintains a strong market position, but its stock has experienced volatility, reflecting broader sentiment shifts in the healthcare sector.
The company repurchased 0.9 million shares for $0.38 billion during the quarter, though this did little to offset the day’s losses as macroeconomic and industry-specific risks weighed on sentiment.
Outlook and Strategic Priorities to Guide Future Performance
Intuitive reaffirmed its full-year guidance, projecting da Vinci procedure growth in the mid-teens range and non-GAAP gross margins of 68% to 69%. The company’s ability to navigate tariff-related challenges and sustain adoption of its latest da Vinci system will be key factors in its performance. With a strong balance sheet and significant cash reserves, Intuitive is well-positioned to manage near-term pressures, but investor confidence may depend on its ability to demonstrate consistent execution amid evolving market conditions.
Updates on tariff mitigation efforts and the continued rollout of new technologies will be closely watched in upcoming communications.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...